• The REQUEST study is now published

    The REQUEST study is a multicenter, prospective study among 7 international centers performing coronary artery bypass grafting procedures.  The primary endpoint was any change in the planned surgical procedure. Major secondary endpoints consisted of the…

    Read more
  • Results for Fourth Quarter and Preliminary Results for Medistim for 2019

    Sales for the quarter ended at MNOK 95.7 (MNOK 97.9), while sales for 2019 ended at MNOK 363.7 (MNOK 325.9), a growth of 11.6%. Q4 2019 PresentationQ4 and preliminary year-end financials 2019

    Read more
  • Investor Presentation, March 3

    Medistim’s CEO Kari E. Krogstad will hold an investor presentation at the Carnegie Healthcare Seminar 2020 in Stockholm, Sweden. Date: Tuesday March 3, 2020 Venue: Regeringsgatan 56. 103 38 Stockholm For more information about this…

    Read more
  • Results for the Third Quarter 2019

    Sales ended at MNOK 85.5 for the quarter (MNOK 77.6), a 10.2 %  growth. Sales as of September increased by 17.6 % and ended at MOK 268.1(MNOK 228.0). Read the full report and presentation below.…

    Read more
  • Medistim has received clearance for sale of MiraQ™ in Japan

    Medistim announces that they have received confirmation from its distributor in Japan that its newest product MiraQ™ is now approved for sale. MiraQ is Medistim's newest generation of products for quality assurance within vascular and…

    Read more
  • Results for the Second Quarter and First Half 2019

    Q2 2019 is the third consecutive quarter with strong growth in both sales revenues and EBIT; 23.1 % and 70.4 % respectively.  Read the full report and presentation below. Medistim Q2 19 presentation 2.quarter 2019

    Read more
  • Results for the First Quarter 2019

    Sales in the first quarter amounted to MNOK 88.7 (MNOK 74.1), a 19.7 % growth. Of the MNOK 14.6 in sales growth, MNOK 11.6 was from the US, where the sales increase in NOK was…

    Read more
  • Annual Report 2018

    During 2018, we reached an important milestone when the final results from the 1000 patients prospective, multi-center registry study REQUEST was presented. In this study, some of the best cardiac centers in Europe, Canada, and…

    Read more
  • Results for Fourth Quarter and Preliminary Results for Medistim for 2018

    Currency neutral sales of own products increased with 25.5 % for the quarter. For 2018, currency neutral growth in sales of own products was 10.0%. EBIT for the quarter ended at MNOK 27.8 (MNOK 16.4),…

    Read more
  • Results for the Third Quarter 2018

    Sales as of September increased by 4.0 % and ended at MOK 228.0 (MNOK 219.2). Revenue from own products showed a currency neutral decline of 0.4 % for the quarter and a currency neutral growth…

    Read more